Citeline Biotech Awards 2026

“This Award will recognise the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases.”

The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognise the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development programme or trial with the largest potential impact in the rare disease space. Outstanding patient-centric processes and innovation in study conduct to overcome the various obstacles of rare disease drug development will also earn high marks.

FINALISTS

• BridgeBio
• C-Further
• Caidya
• Cerenome
• CSL Behring
• F2G
• KalVista, a company of the Chiesi Group
• NorthSea Therapeutics
• Polaryx Therapeutics
• PureTech Health
• Regeneron Pharmaceuticals
• Servier Pharmaceuticals

“Biotech companies are redefining the future of cancer treatment combining cutting-edge science with an unwavering focus on patients who need new options most. This Award celebrates those leading that charge.”

Cancer drug development has been transformed by the biotech sector. From pioneering immuno-oncology approaches to precision medicine and novel targeted therapies, biotech companies have consistently pushed the boundaries of what is scientifically and clinically possible in oncology. Operating with speed, scientific conviction, and a willingness to tackle the hardest problems, biotech organisations have become the engine of oncology innovation bringing first-in-class and best-in-class therapies to patients who have long faced limited options. This Award will recognize a biotech company that has demonstrated outstanding achievement in the research, development, or clinical execution of an oncology program, and whose work reflects the very best of what the biotech model can deliver.

FINALISTS

• Arcus Biosciences with The START Center for Cancer Research
• BriaCell Therapeutics
• Candel Therapeutics
• Celcuity
• Intensity Therapeutics
• Kairos Pharma
• Legend Biotech
• ModeX Therapeutics

“Biotech companies are redefining what is possible in neuroscience bringing bold science and relentless focus to conditions that have long resisted progress. This Award celebrates those at the frontier of that effort.”

Neurological and psychiatric conditions represent some of the most scientifically complex and historically underserved areas of medicine. Biotech companies have increasingly become the driving force behind bold, first-in-class approaches to these devastating diseases bringing scientific creativity, agility, and patient focus to an area where large-scale drug development has historically struggled to deliver. This Award will recognize a biotech company that has demonstrated outstanding achievement in the research, development, or clinical execution of a neuroscience program. The judges will be looking for a company that has leveraged the unique strengths of the biotech model speed, innovation, and scientific conviction to meaningfully advance the standard of care or address a significant unmet medical need in neurology or psychiatry.

FINALISTS

• Autobahn Therapeutics
• Draig Therapeutics
• Ionis Pharmaceuticals
• Rapport
• Syndeio Biosciences
• Takeda

“The judges will be looking to reward the high-performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.”

The winning biotech research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high-performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

FINALISTS

• Alveus Therapeutics
• CG Oncology
• PolyPid
• Regeneron Pharmaceuticals (Otarmeni^™ Clinical Development Team)
• Revival Research Institute (Clinical Operations & Site Network Team)

“This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2025/26.”

This Award will be presented to two or more organisations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2025/26. Partnerships for this award must be between a pharmaceutical or biotech company and a contract research organisation.

FINALISTS

• Caidya
• CeleCor Therapeutics and Everest Clinical Research
• Champions Oncology and Nimbus Therapeutics
• ICON and Akero Therapeutics
• ICON and Supernus Pharmaceuticals
• Kestrel Therapeutics and Seuss+
• Opus Genetics and Mintra Health
• ProPharma and Agencia

“This Award will recognize a technology solution that has moved beyond promise and into proven impact transforming the way clinical research is conducted and setting a new benchmark for innovation across the industry.”

Technology is fundamentally reshaping the way clinical research is designed, conducted, and delivered. From artificial intelligence and machine learning to decentralised trial platforms, digital biomarkers, and advanced data analytics, the application of innovative technology across the drug development continuum is accelerating timelines, improving data quality, reducing patient burden, and unlocking insights that were previously out of reach. This Award will recognize a company or team that has developed or applied a technology-driven solution that has made a measurable and demonstrable impact on clinical research or drug development. The judges will be looking for innovations that go beyond incremental improvement solutions that are genuinely transformative, scalable, and represent a meaningful step forward for the industry.

FINALISTS

• Aidar Health (MouthLab^™ / AIDI^™)
• Brainomix
• Clinion AI Technologies
• Emulate
• intoDNA
• IXICO
• Mural Health
• Nabsys 2.0
• PPD^™ clinical research business of Thermo Fisher Scientific
• TransPerfect Life Sciences

“This Award celebrates those who have made a genuine and lasting commitment to ensuring that the patient voice is not just heard but acted upon placing the people at the heart of clinical research firmly at the centre of every decision.”

At the heart of every clinical trial, every drug development program, and every regulatory milestone is a patient. The most meaningful advances in clinical research are not measured solely in data points and endpoints they are measured in the lives changed, the burdens reduced, and the voices heard. Across the biopharmaceutical industry, a growing number of organisations are embedding patient centricity not as a principle, but as a practice fundamentally redesigning how trials are conceived, conducted, and communicated with the patient experience at the centre. This Award will recognize a company, team, or individual that has demonstrated an exceptional and authentic commitment to putting patients first going beyond compliance and convention to ensure that the needs, preferences, and perspectives of patients genuinely shape the way clinical research is designed and delivered.

The judges will be looking for entries that demonstrate real, measurable impact on the patient experience not simply good intentions or standard practice. Evidence of meaningful collaboration with patients and patient advocacy groups, innovative approaches to reducing patient burden, and a demonstrable shift in how the organisation thinks and operates will all be highly valued.

FINALISTS

• Acumen Pharmaceuticals
• Eisai
• Entrada Therapeutics
• Mural Health (Patient Kindness)
• Revival Research Institute
• Shanghai Henlius Biotech
• Travere Therapeutics

“This Award will recognise the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare.”

The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

FINALISTS

• BridgeBio
• Celcuity
• Dizal Pharmaceutical
• PolyPid
• Revolution Medicines
• Shanghai Henlius Biotech

“With this award, we are looking to recognise the accomplishments of an exceptional individual with a consistent history of significant contributions to the biotech research and development field.”

This award will go to someone who has had a distinguished career in R&D or clinical research, working at a biotech company. The nominee should have a history of successful projects that have had a positive impact on human health. Metrics can include scientific publications and citations; patents and involvement in innovation; involvement in clinical trials and drug approvals; and contributions to the development of future scientists and leaders in the field through mentorship, training programmes, and leadership roles in professional organisations.

“The Bio Pharma Company of the Year Award is the most coveted recognition of the evening celebrating an organisation that has excelled across every dimension of what it means to be a leader in biopharmaceutical research and development, and whose work during the qualifying period has made a genuine and lasting contribution to the advancement of human health.”

The biopharmaceutical industry demands extraordinary things from the organisations that operate within it. Scientific excellence, clinical execution, commercial acumen, and an unwavering commitment to patients must all be sustained simultaneously often in the face of significant uncertainty, resource constraints, and the relentless pressure of an industry where the stakes could not be higher. This Award will recognize the biopharmaceutical or biotech company that has demonstrated the most outstanding overall performance across the clinical research and drug development landscape during the qualifying period. This is the most prestigious award of the evening a recognition not of a single achievement, but of an organisation that has excelled across multiple dimensions and demonstrated what it truly means to be a leader in this industry.

The judges will be looking for a company that has made a measurable and meaningful impact across a broad range of activities from scientific innovation and clinical execution to patient engagement, partnerships, and organisational culture. A compelling Company of the Year entry will tell a coherent story of an organisation firing on all cylinders, whose collective achievements during the qualifying period set it apart from its peers and reflect a clear and authentic commitment to advancing human health.